{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:53:47Z","timestamp":1790636027934,"version":"4.1.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C\n                    <jats:italic>gag<\/jats:italic>\n                    vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, placebo-controlled clinical trials in healthy HIV-1-uninfected adults. Escalating doses of AVX101 or placebo were administered subcutaneously to participants in the United States and Southern Africa. Because of vaccine stability issues, the first trial was halted prior to completion of all dose levels and a second trial was implemented. The second trial was also stopped prematurely due to documentation issues with the contract manufacturer. Safety and immunogenicity were evaluated through assessments of reactogenicity, reports of adverse events, and assessment of replication-competent and Venezuelan equine encephalitis (VEE) viremia. Immunogenicity was measured using the following assays: enzyme-linked immunosorbent assay (ELISA), chromium 51 (\n                    <jats:sup>51<\/jats:sup>\n                    Cr)-release cytotoxic T lymphocyte (CTL), gamma interferon (IFN-\u03b3) ELISpot, intracellular cytokine staining (ICS), and lymphoproliferation assay (LPA). Anti-vector antibodies were also measured. AVX101 was well tolerated and exhibited only modest local reactogenicity. There were 5 serious adverse events reported during the trials; none were considered related to the study vaccine. In contrast to the preclinical data, immune responses in humans were limited. Only low levels of binding antibodies and T-cell responses were seen at the highest doses. This trial also highlighted the difficulties in developing a novel vector for HIV.\n                  <\/jats:p>","DOI":"10.1128\/cvi.00258-12","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T20:36:59Z","timestamp":1345667819000},"page":"1651-1660","source":"Crossref","is-referenced-by-count":64,"title":["Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C\n                    <i>gag<\/i>\n                    Vaccine in Healthy HIV-1-Uninfected Adults"],"prefix":"10.1128","volume":"19","author":[{"given":"M.","family":"Wecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pensiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Lin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Abdool Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2012,8,22]]},"reference":[{"key":"key20180919073627_B1","first-page":"199","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am. Stat."},{"key":"key20180919073627_B2","volume-title":"AVX101 clinical investigators brochure","author":"AlphaVax, Inc","year":"2004"},{"key":"key20180919073627_B3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0264-410X(01)00485-6","article-title":"Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses","volume":"20","author":"Balasuriya","year":"2002","journal-title":"Vaccine"},{"key":"key20180919073627_B4","doi-asserted-by":"crossref","first-page":"10623","DOI":"10.1128\/JVI.74.22.10623-10630.2000","article-title":"Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles","volume":"74","author":"Balasuriya","year":"2000","journal-title":"J. Virol."},{"key":"key20180919073627_B5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073627_B6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1073\/pnas.87.2.523","article-title":"Myristoylation-dependent replication and assembly of human immunodeficiency virus 1","volume":"87","author":"Bryant","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073627_B7","first-page":"P11","article-title":"Safety and immunogenicity of an alphavirus replicon HIV Gag vaccine (AVX101) in healthy HIV-uninfected adults","volume":"11","author":"Chulay","year":"2006","journal-title":"Antivir. Ther."},{"key":"key20180919073627_B8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/JVI.74.1.371-378.2000","article-title":"Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles","volume":"74","author":"Davis","year":"2000","journal-title":"J. Virol."},{"key":"key20180919073627_B9","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1073\/pnas.86.15.5781","article-title":"Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1","volume":"86","author":"Gottlinger","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073627_B10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/339677","article-title":"Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon","volume":"185","author":"Lee","year":"2002","journal-title":"J. Infect. Dis."},{"key":"key20180919073627_B11","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect. Immun."},{"key":"key20180919073627_B12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jim.2006.07.015","article-title":"Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials","volume":"315","author":"Moodie","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"key20180919073627_B13","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J. Clin. Invest."},{"key":"key20180919073627_B14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1089\/aid.1990.6.721","article-title":"Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly","volume":"6","author":"Pal","year":"1990","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"key20180919073627_B15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"key":"key20180919073627_B16","article-title":"Preclinical immunogenicity studies on pilot lots of a prototype VEE replicon vector HIV-1 subtype C vaccine for South Africa, abstr 175. Abstr","author":"Reap","year":"2001"},{"key":"key20180919073627_B17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2307\/2531456","article-title":"A modified Bonferroni method for discrete data","volume":"46","author":"Tarone","year":"1990","journal-title":"Biometrics"},{"key":"key20180919073627_B18","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/JVI.75.6.2660-2664.2001","article-title":"Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein","volume":"75","author":"Wilson","year":"2001","journal-title":"J. Virol."},{"key":"key20180919073627_B19","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"key20180919073627_B20","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1128\/JVI.68.4.2556-2569.1994","article-title":"Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids","volume":"68","author":"Zhou","year":"1994","journal-title":"J. Virol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00258-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T16:46:39Z","timestamp":1627577199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00258-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,22]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,9,26]]},"published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1128\/CVI.00258-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00258-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,22]]}}}